Hepatocellular Carcinoma with VP3/4 Portal Vein Tumor Thrombus
Conditions
Interventions
Trial group 1:Demand-based immune-enhanced TACE therapy (precise embolization via microcatheter superselective catheterization into tumor-feeding arteries targeting 1-3 lesions) combined with targeted
Trial group 2:Precise radiotherapy (4D-MRI combined with abdominal compression technique, hypofractionated regimen of 3Gy × 12-15 fractions) combined with targeted immunotherapy (camrelizumab 200mg Q3
Control group:Monotherapy with targeted immunotherapy (camrelizumab 200mg Q3W, apatinib mesylate tablets 250mg QD)
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically or radiologically confirmed HCC; 2. Grade VP3/4 portal vein tumor thrombus; 3. Child-Pugh score =12 weeks; 5. No prior systemic therapy for HCC, or an interval of >=1 month since last local treatment; 6. Age >=18 years, all genders.
Exclusion criteria
Exclusion criteria: 1. Presence of malignancies other than HCC; 2. Presence of severe cardiac, cerebral, renal, or pulmonary diseases or dysfunction; 3. History of gastrointestinal bleeding within 6 months prior to initiation; 4. Patients who have received or are scheduled for organ or bone marrow transplantation; 5. Patients currently on immunosuppressive agents or systemic corticosteroid therapy; 6. Patients with known hypersensitivity to the investigational drug or its excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serious Adverse Event;Disease Control Rate;Objective Response Rate;Progression-Free Survival;Adverse Event; | — |
Countries
China
Contacts
Public ContactZhang Yonghong
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed